



Innovative back microsurgery

Press release

2013 sales: x2.2 to €6.1 million

Robust growth in all regions

SpineJack® sales: x5 in 2 years

Nearly 9,000 SpineJack® implanted to date

Toulouse, January 16, 2014 - VEXIM (FR0011072602 - ALVXM), a medical device company specialized in minimally invasive solutions for the treatment of vertebral fractures, today reported 2013 4th quarter and full-year consolidated sales.

Q4 2013: doubling of sales for 6th consecutive quarter

	Quarter			FY		
	Q4 2013	Q4 2012	Change	2013	2012	Change
Sales (€ '000s)	2,026	974	x2.1	6,123	2,742	x2.2

VEXIM recorded 2013 fourth quarter sales of €2 million, up by a multiple of 2.1 from the same period in 2012. With more than 1,500 implants posed over the quarter, sustained growth of SpineJack® sales confirmed its successful inroads with spine surgeons. On that momentum, nearly 9,000 SpineJack® have been implanted in France and other countries since its commercial release.

2013: a new period of robust growth in all regions

For the full year, sales rose by a multiple of 2.2 to €6.1 m. Since 2011, when the direct sales strategy for SpineJack® was first launched, sales have increased fivefold. At December 31, 2013, direct sales accounted for 92% of total volume, up from just one third at the end of 2011.

Vincent Gardès, CEO of VEXIM, commented: *"We have been successful in maintaining a trajectory of strong quarter-to-quarter growth, demonstrating the relevance of our direct sales strategy. Through continuing commercial development in Europe, supplemented by use of specialized distribution channels in other global regions, our goal of becoming the market leader in spinal trauma segment is becoming a reality "*

2014 preliminary financial agenda*:

FY 2013 results: March 15, 2014

H1 2014 sales: July 20, 2014

*Indicative dates, subject to potential modifications

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital¹ and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3rd 2012.

For further information, please go to www.vexim.com

SpineJack®², a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

Contacts

VEXIM

Vincent Gardès

CEO

Tel: +33 5 61 48 48 38

shareholders@vexim.com

NewCap.

Financial Communications
and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol

caroline@alizerp.com

Tel: +33 6 64 18 99 59

Christian Berg

christian@alizerp.com

Tel: +33 1 70 22 53 86



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

² This medical device is a regulated health product that, with regard to these regulations, bears the CE mark.
Please refer to the Instructions for Use.